Steve Schonfeld’s Regenxbio RGNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-14,151
Closed -$119K 2935
2026
Q1
$119K Buy
+14,151
New +$149K ﹤0.01% 1855
2024
Q4
Sell
-124,632
Closed -$1.31M 2328
2024
Q3
$1.31M Buy
124,632
+75,512
+154% +$921K 0.01% 1065
2024
Q2
$575K Sell
49,120
-134,675
-73% -$2.1M ﹤0.01% 1432
2024
Q1
$3.87M Buy
+183,795
New +$3.27M 0.03% 735
2022
Q4
Sell
-7,578
Closed -$200K 2943
2022
Q3
$200K Buy
+7,578
New +$225K ﹤0.01% 2343
2019
Q4
Sell
-10,900
Closed -$387K 1462
2019
Q3
$387K Sell
10,900
-31,400
-74% -$1.27M 0.01% 718
2019
Q2
$2.17M Sell
42,300
-46,800
-53% -$2.34M 0.08% 275
2019
Q1
$5.11M Buy
+89,100
New +$4.41M 0.18% 155
2018
Q4
Sell
-25,700
Closed -$1.94M 1209
2018
Q3
$1.94M Sell
25,700
-84,200
-77% -$6.07M 0.09% 288
2018
Q2
$7.89M Buy
109,900
+59,900
+120% +$2.86M 0.43% 52
2018
Q1
$1.49M Sell
50,000
-108,687
-68% -$3.16M 0.11% 249
2017
Q4
$5.28M Buy
158,687
+18,567
+13% +$559K 0.43% 62
2017
Q3
$4.62M Buy
140,120
+65,120
+87% +$1.47M 0.42% 72
2017
Q2
$1.48M Sell
75,000
-1,911
-2% -$37K 0.15% 199
2017
Q1
$1.49M Buy
76,911
+36,911
+92% +$712K 0.15% 192
2016
Q4
$742K Buy
+40,000
New +$764K 0.1% 270

Other funds holding RGNX

Steve Schonfeld's RGNX Position: Q2 2026 in Review

Steve Schonfeld sold out of Regenxbio (RGNX) in Q2 2026, closing a stake of 14,151 shares — an estimated $119K sold.

Steve Schonfeld first reported a position in RGNX in Q4 2016 and held it in 16 quarters. The position peaked at $7.89M in Q2 2018. 164 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

  • Steve Schonfeld reported no remaining Regenxbio position as of Q2 2026 after selling out during the quarter.
  • Steve Schonfeld sold 14,151 Regenxbio shares in Q2 2026, an estimated $119K.
  • Steve Schonfeld first reported a position in Regenxbio in Q4 2016 and held it in 16 quarters.
  • Steve Schonfeld's Regenxbio position peaked at $7.89M in Q2 2018.
  • 164 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.